Last updated: July 18, 2026
ACCURETIC (quinapril + hydrochlorothiazide): investment scenario and fundamentals analysis for FDA status, patent risk, and generic/biosimilar outlook
ACCURETIC is a fixed-dose combination of quinapril (ACE inhibitor) + hydrochlorothiazide (thiazide diuretic). For investment-grade decisioning, the key fundamentals are (1) US regulatory status via FDA labeling and Orange Book listings, (2) patent/market exclusivity runway for the specific dosage strengths and dosage forms, (3) generic entry risk after patent and exclusivity expiry, and (4) the affordability dynamics typical for mature antihypertensive combinations.
This profile focuses on US market exclusivity and patent defensibility, since that is the primary driver of future gross-to-net erosion and launch timing for generics in older cardiovascular products.
What is ACCURETIC (quinapril hydrochlorothiazide) and how is it marketed in the US?
Quick read: ACCURETIC is used for hypertension and is sold as an oral fixed-dose tablet combination (ACE inhibitor + thiazide diuretic). Investment implications come from the fact that older antihypertensives are usually highly contestable once formulation and method patents are exhausted, and value typically shifts from innovation to manufacturing scale, procurement, and distribution economics.
What therapeutic category does ACCURETIC fall into?
- Cardiovascular: hypertension
- Drug classes: ACE inhibitors and thiazide diuretics
- Mechanistic risk profile: low risk of “black box” reversals versus novel assets, but pricing is exposed to generic substitution
What dosage forms and strengths matter for exclusivity?
For combination products, the legal and regulatory question is typically per-strength and per-formulation. Orange Book listings can differ by:
- tablet strength (e.g., quinapril mg and HCTZ mg combinations)
- formulation composition (inactive ingredients can matter for formulation patents)
- manufacturing process patents (rare but possible for legacy products)
What patents protect ACCURETIC in the US and how many are listed?
Quick read: Investment defensibility for a mature combination product is determined by the number of Orange Book patents tied to the listed NDA and their remaining life. For fixed-dose ACEi/HCTZ combinations, generic entry risk usually concentrates on:
- formulation patents (composition of matter or formulation-specific)
- method-of-use patents (less common for classic hypertension indications, but can exist)
- device or manufacturing method patents (rare for older tablets, but can appear)
How to interpret the patent estate for a fixed-dose ACE inhibitor + diuretic
- Composition of matter patents are the strongest but often expired for older actives.
- Formulation and process patents are the most likely remaining barriers for generic challengers.
- Method-of-use patents can create “carve-outs” for generic label design, but they tend to be harder to enforce when indications are broad and well established.
Where investment teams find “real barriers”
For ACCURETIC, the actionable investment inputs are:
- Orange Book patent coverage by NDA
- patent expiration dates
- use code and patent scope indicators
- whether ANDA filings are pending with Para IV notices (if any)
When does ACCURETIC lose exclusivity, including patent expiry and FDA exclusivity periods?
Quick read: For mature cardiovascular fixed-dose combinations, the expected pattern is:
- composition-related exclusivity has long expired,
- remaining exclusivity is usually patent-specific (often last through a late formulation/process patent), and
- once those barriers clear, generic competition typically accelerates quickly.
Exclusivity vs patents: what drives entry timing?
- Market exclusivity (e.g., new chemical entity, new clinical investigation, pediatric) applies only in limited circumstances and often does not control older cardiovascular drugs.
- Patent expiration (Orange Book listed patents) is the dominant driver.
- Hatch-Waxman timeline: if an ANDA is filed with a Para IV certification, the FDA approval clock and any litigation-driven stays control real entry windows.
Investment consequence
- If ACCURETIC’s remaining Orange Book patents are few and nearing expiry, the product’s forward margin profile usually compresses sharply due to generic price erosion and wholesaler rebate pressure.
What Orange Book status does ACCURETIC have, and what are the listed patent numbers?
Quick read: Orange Book status is the starting point for Para IV and launch timing models. The decision-critical deliverables typically include:
- NDA number(s)
- listed Orange Book patents
- expiration dates
- drug substance vs drug product vs method coverage
- regulatory exclusivity dates (if listed)
What to extract for an investment model
- NDA listing(s) for each strength
- patent list with (a) patent type (b) expiration (c) exclusivity code
- any multiple entry doors created by differing strength coverage
What generic entry risks exist for ACCURETIC, and how does Paragraph IV litigation work here?
Quick read: The generic threat for ACCURETIC is usually driven by whether any ANDAs are certified with Paragraph IV and whether that triggers automatic 30-month stays or results in settlement-triggered design-around.
How Para IV changes the economics
If any ANDA sponsor challenges Orange Book patents, investment scenarios split into:
- Stay scenario: generic approval delayed due to litigation
- Invalidity/non-infringement success: generic launch earlier than the patent expiry date
- Settlement with “carve-out” design: delayed launch but with entry protected by specific label or formulation restrictions
Typical antihypertensive contestability dynamics
- Generic substitution is strong for widely prescribed, off-patent cardiovascular drugs.
- If ACCURETIC’s patent estate is thin, multiple generic applicants often accelerate price competition after expiry.
Has ACCURETIC faced any patent litigation, settlements, or FDA disputes?
Quick read: Patent litigation is the highest signal for whether ACCURETIC has non-obvious remaining protection. A litigation or settlement record would materially change:
- effective launch dates
- strength-by-strength entry timing
- expected competitive set in each channel
What matters in enforcement outcomes
For fixed-dose products, the legal record is often about:
- infringement of formulation or process patents
- whether the generic can omit/modify specific components
- whether litigation results in an agreed entry date (reverse-payment style settlements are possible under Hatch-Waxman, subject to law and settlement structures)
How does ACCURETIC compare with competing quinapril plus hydrochlorothiazide brands and approved generics?
Quick read: The competitive frame for ACCURETIC is not “within-class innovation.” It is:
- equivalent generics (same active ingredients and dosage strength)
- therapeutic substitutions (other ACEi/HCTZ combinations and other BP regimens)
- payer formularies favoring lowest net cost
Practical competitive implications for investors
- If ACCURETIC’s net price advantage erodes, uptake shifts to cheaper AB-rated equivalents.
- If ACCURETIC maintains strong formulary status, gross-to-net compression can be slower even after patent expiry.
Benchmarks used by investors
- number of AB-rated alternatives
- NDC-level share losses post-first generic entry
- rebate and incentive structures tied to formulary positioning
What dosage strengths and labeling aspects influence patent coverage for ACCURETIC?
Quick read: For legacy fixed-dose tablets, exclusivity and patent exposure are strength-specific. Patent claims can cover:
- specific quinapril/HCTZ ratios
- manufacturing attributes tied to API ratio or tablet properties
- stability or impurity profiles linked to the drug product
Label and indication scope
Investment sensitivity increases if:
- the label is narrower in a way that preserves a method-of-use claim
- generic label design is restricted due to patent scope or settlement terms
What manufacturing and IP barriers could delay generic entry for ACCURETIC?
Quick read: For older oral tablets, manufacturing barriers usually rank below patent barriers. Still, investors check:
- process patents tied to impurity control
- formulation patents tied to tablet dissolution or stability
- supply chain constraints for the specific NDC
Typical technical/IP patterns for fixed-dose tablets
- process improvements are sometimes patented even when actives are old
- excipient selection and tablet characteristics can be part of formulation patent claims
- any manufacturing patents can slow launch even after core patent expiry
Investment scenario modeling: best case, base case, and downside case for ACCURETIC
Quick read: Without inserting speculative dates, the correct investment framework is scenario-based on remaining Orange Book life and Para IV/litigation outcomes. The scenario logic for an older cardiovascular combination like ACCURETIC is:
Base case (patents near expiry; limited ongoing exclusivity)
- Competitive pressure increases as patents expire strength by strength.
- Price erosion is driven by increased generic competition.
- Profitability is increasingly determined by cost structure, rebate performance, and payer contracting.
Downside case (unexpected active patent estate or settlement prolongs exclusivity elsewhere but leaves one strength exposed)
- The product portfolio can split in profitability by strength.
- If a major strength loses exclusivity earlier than expected, share and net price drop can be abrupt.
Best case (strong remaining patent coverage or litigation keeps Para IV outcomes from landing)
- Entry is delayed or limited to fewer strengths.
- Higher net price sustainability improves cash flow predictability.
Regulatory and commercialization questions investors should map for ACCURETIC
Quick read: For generic entry timing, the critical regulatory milestones are:
- Orange Book expiration dates
- any ANDA Para IV activity and resulting FDA approval dates
- AB-rating and generic substitution timing in real-world formularies
What to monitor after patent expiry
- NDC-level launch behavior (who launches first, who follows)
- distribution stocking patterns
- payer formulary updates and formulary tier shifts
Key Takeaways
- ACCURETIC is a mature, fixed-dose quinapril + hydrochlorothiazide oral hypertension product where future value is primarily determined by Orange Book patent coverage and any Para IV litigation/settlement outcomes rather than clinical differentiation.
- Investment upside typically requires evidence of meaningful remaining patent life or ongoing litigation that delays generic substitution.
- Investment downside is driven by early loss of patent barriers strength-by-strength, resulting in fast channel-wide gross-to-net compression.
- The strongest action items for a fundamentals model are NDA-level Orange Book mapping, patent expiry calendar, and any ANDA Para IV/litigation record tied to those patents.
FAQs
1) What does ACCURETIC’s Orange Book listing typically control for generic competition?
It controls which patents the FDA considers in Hatch-Waxman certifications, driving Para IV strategy and the likelihood of a 30-month stay or litigation-based launch delays.
2) How does generic substitution usually impact net price for older ACEi/thiazide combinations like ACCURETIC?
It compresses net pricing quickly as AB-rated generics gain formulary and pharmacy uptake, increasing rebate pressure.
3) What kinds of ACCURETIC patents matter most to an ANDA challenger?
Formulation or manufacturing-process patents tied to the listed drug product and strength are typically the most enforceable remaining barriers in older fixed-dose tablets.
4) Can labeling design affect whether a generic can launch against ACCURETIC?
Yes, if any method-of-use patents exist or if settlements restrict label language tied to specific indications or patient populations.
5) What is the most common pathway for generic erosion after exclusivity ends for ACCURETIC?
Stepwise strength-by-strength entry, followed by broader pharmacy substitution and payer tier downgrades, typically leading to multi-quarter gross-to-net declines.
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. Hatch-Waxman Act and Paragraph IV Certification overview materials. https://www.fda.gov/
